Sign in to continue:

Monday, July 27th, 2026

Columbia Financial, Inc. Files Amended Q1 2026 10-Q/A to Correct Executive Officer Certification Exhibits 55

Columbia Financial, Inc. 10-Q/A Report Q1 2026: Key Insights for Investors

Columbia Financial, Inc. (Nasdaq: CLBK) Files Amended Q1 2026 Report – Key Details for Investors

Overview

Columbia Financial, Inc., the parent company of Columbia Bank and a key financial institution based in New Jersey, has filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. This amendment provides corrected versions of critical exhibits relating to executive officer certifications, specifically correcting the officer referenced as the Company’s principal financial and accounting officer. The amendment explicitly states that no other financial disclosures or results were changed from the original filing.

Key Points from the Report

  • Amendment Purpose: The sole reason for this amendment is to furnish the correct versions of Exhibit 31.2 and Exhibit 32. Previously, these exhibits incorrectly identified the Company’s principal financial officer. The amendment corrects this to reference the Executive Vice President and Chief Financial Officer, not the First Senior Executive Vice President and Chief Banking Officer.
  • No Change to Financials: The company emphasizes that there are no changes to the financial results, disclosures, or other substantive content of the originally filed Q1 2026 Form 10-Q.
  • Outstanding Shares Update: As of June 5, 2026, there are 144,058,235 shares of common stock issued and outstanding, including 76,016,524 shares held by Columbia Bank, MHC.
  • SEC Compliance: The company affirms it has filed all required reports and submitted all Interactive Data Files as mandated by SEC regulations over the past 12 months.
  • Filing Status: Columbia Financial, Inc. is classified as an Accelerated Filer but not a Large Accelerated Filer, Smaller Reporting Company, or Emerging Growth Company.
  • Not a Shell Company: The company certifies it is not a shell company under SEC rules.

Important Information for Shareholders

  • Correction of Executive Certification: The amendment addresses a technical but important compliance issue related to Sarbanes-Oxley Act certifications. The correct identification of the executive officer responsible for financial statements is a regulatory requirement and is critical for legal and governance reasons.
  • No Impact on Earnings or Operations: Since the amendment does not alter any financial statement, operational disclosure, or business outlook, there is no direct impact on the company’s earnings, assets, liabilities, or forward guidance.
  • Share Count Clarity: The explicit statement of shares outstanding, including the large block held by Columbia Bank, MHC, is important for investors assessing ownership structure and potential float.

Potential Price Sensitivity

Limited Price-Sensitive Information: This filing does not contain any new financial data, earnings revisions, regulatory actions, or operational developments that would typically be considered price-sensitive. The amendment is solely for compliance correction of officer certification references.

Investor Takeaway

For investors, the main takeaway is a confirmation of the company’s adherence to SEC compliance and good governance practices. There is no change to Columbia Financial’s financial condition, performance, or outlook as a result of this amendment.

Unless the market is particularly sensitive to compliance and governance minutiae, this filing is not expected to materially move the share price.


Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should review the full SEC filings and consult with their financial advisors before making investment decisions.


View Columbia Financial, Inc. Historical chart here



AN2 Therapeutics, Inc. Files Form 8-K Current Report with SEC – Company Information and Filing Details

AN2 Therapeutics, Inc. (NASDAQ: ANTX) Announces Results of 2...

W&T Offshore Reports Strong Q1 2026 Financial Results, Increases Production and Declares Dividend

W&T Offshore Reports Strong Q1 2026 Results; Declares Divide...

Bausch Health Companies Inc. (BHC) 8-K SEC Filing Details, Address, and Company Information – February 26, 2026

Bausch Health Companies Amends 2023 Performance Share Units ...